The FDA lifts a partial hold on Mersana's top drug -- and then its shares crater
Mersana $MRSN and the FDA have come up with a newly revised development program for the biotech’s lead drug just a couple months after a patient’s death triggered a partial hold on enrolling more people for the study.
From the beginning, Mersana noted that the death may have been caused by XMT-1522, an antibody drug conjugate designed to drop a therapeutic payload on HER2-expressing tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.